WG
BCRX icon

Winton Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Winton Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Buy
255,600
+202,384
+380% +$1.83M 0.08% 254
2026
Q1 		$507K Buy
53,216
+37,616
+241% +$292K 0.02% 708
2025
Q4 		$122K Buy
+15,600
New +$113K ﹤0.01% 867
2019
Q2 		– Sell
-15,353
Closed -$125K – 1129
2019
Q1 		$125K Buy
+15,353
New +$131K ﹤0.01% 1015

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Winton Group's BCRX Position: Q2 2026 in Review

Winton Group increased its BioCryst Pharmaceuticals (BCRX) stake by 380% in Q2 2026, buying an estimated $1.83M and bringing the position to 255,600 shares worth $2.56M. The position accounts for 0.08% of the portfolio, ranked #254.

Winton Group first reported a position in BCRX in Q1 2019 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Winton Group held 255,600 shares of BioCryst Pharmaceuticals worth $2.56M as of Q2 2026.
  • Winton Group bought 202,384 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $1.83M.
  • BioCryst Pharmaceuticals made up 0.08% of Winton Group's portfolio in Q2 2026, its #254 holding.
  • Winton Group first reported a position in BioCryst Pharmaceuticals in Q1 2019 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.